Impact of Dexamethasone Responsiveness on Long Term Outcome in Patients with Newly Diagnosed Multiple Myeloma

Dexamethasone (Dex), alone or in combination, is commonly used for treating multiple myeloma. Dex as single agent for initial therapy of myeloma results in overall response rates of 50-60%. It is unclear whether steroid responsiveness reflects any biological characteristic that impacts long-term out...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Sinha, Shirshendu, Rajkumar, S. Vincent, Lacy, Martha Q., Hayman, Suzanne R., Buadi, Francis K., Dispenzieri, Angela, Dingli, David, Kyle, Robert A., Gertz, Morie A., Kumar, Shaji
Formato: Artigo
Idioma:Inglês
Publicado em: 2009
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2864312/
https://ncbi.nlm.nih.gov/pubmed/19958361
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2141.2009.08023.x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados